Durso Jerome Benedict 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jan 31, 2023
Insider Transaction Report
Form 4
Durso Jerome Benedict
Chief Operating Officer
Transactions
- Award
Common Stock
2023-01-27+50,400→ 154,640 total - Award
Option to Purchase Common Stock
2023-01-27+82,700→ 82,700 totalExercise: $18.40Exp: 2033-01-27→ Common Stock (82,700 underlying)
Footnotes (2)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023.
- [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023.